Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Attribution of 12 High-Risk Human Papillomavirus Genotypes to Infection and Cervical Disease
Elmar A. Joura, Kevin A. Ault, F. Xavier Bosch, et al.
Cancer Epidemiology Biomarkers & Prevention (2014) Vol. 23, Iss. 10, pp. 1997-2008
Open Access | Times Cited: 168

Showing 26-50 of 168 citing articles:

Human papillomavirus vaccination: The ESGO–EFC position paper of the European society of Gynaecologic Oncology and the European Federation for colposcopy
Elmar A. Joura, Maria Kyrgiou, Francisco Xavier Bosch, et al.
European Journal of Cancer (2019) Vol. 116, pp. 21-26
Open Access | Times Cited: 47
Comparison of the long‐term impact and clinical outcomes of fewer doses and standard doses of human papillomavirus vaccine in the United States: A database study
Ana M. Rodrı́guez, Burak Zeybek, Micah Vaughn, et al.
Cancer (2020) Vol. 126, Iss. 8, pp. 1656-1667
Open Access | Times Cited: 43
Immunogenicity and safety of a nine-valent human papillomavirus vaccine in women 27–45 years of age compared to women 16–26 years of age: An open-label phase 3 study
Elmar A. Joura, Àngels Ulied, Corinne Vandermeulen, et al.
Vaccine (2021) Vol. 39, Iss. 20, pp. 2800-2809
Open Access | Times Cited: 33
9-Valent HPV vaccine for cancers, pre-cancers and genital warts related to HPV
Punnee Pitisuttithum, Christine Velicer, Alain Luxembourg
Expert Review of Vaccines (2015) Vol. 14, Iss. 11, pp. 1405-1419
Closed Access | Times Cited: 45
Update on the new 9-valent vaccine for human papillomavirus prevention.
David Yi Yang, Keyna Bracken
PubMed (2016) Vol. 62, Iss. 5, pp. 399-402
Closed Access | Times Cited: 45
Estimating the cost-effectiveness profile of a universal vaccination programme with a nine-valent HPV vaccine in Austria
Louis Boiron, Elmar A. Joura, Nathalie Largeron, et al.
BMC Infectious Diseases (2016) Vol. 16, Iss. 1
Open Access | Times Cited: 44
Potential impact of a nonavalent HPV vaccine on HPV related low-and high-grade cervical intraepithelial lesions: A referral hospital-based study in Sicily
Giuseppina Capra, Lucia Giovannelli, Domenica Matranga, et al.
Human Vaccines & Immunotherapeutics (2017) Vol. 13, Iss. 8, pp. 1839-1843
Open Access | Times Cited: 44
Efficacy, Immunogenicity, and Safety of a 9-Valent Human Papillomavirus Vaccine: Subgroup Analysis of Participants From Asian Countries
Suzanne M. Garland, Punnee Pitisuttithum, Hys Ngan, et al.
The Journal of Infectious Diseases (2018) Vol. 218, Iss. 1, pp. 95-108
Open Access | Times Cited: 43
Comparison of HPV prevalence between HPV-vaccinated and non-vaccinated young adult women (20–26 years)
Fangjian Guo, Jacqueline M. Hirth, Abbey B. Berenson
Human Vaccines & Immunotherapeutics (2015) Vol. 11, Iss. 10, pp. 2337-2344
Open Access | Times Cited: 41
Human papillomavirus vaccine trials and tribulations
Marc Z. Handler, Nancy S. Handler, Sławomir Majewski, et al.
Journal of the American Academy of Dermatology (2015) Vol. 73, Iss. 5, pp. 743-756
Closed Access | Times Cited: 41
The Valgent4 protocol: Robust analytical and clinical validation of 11 HPV assays with genotyping on cervical samples collected in SurePath medium
Jesper Bonde, Ditte Møller Ejegod, Kate Cuschieri, et al.
Journal of Clinical Virology (2018) Vol. 108, pp. 64-71
Open Access | Times Cited: 40
Voltammetric determination of human papillomavirus 16 DNA by using interdigitated electrodes modified with titanium dioxide nanoparticles
N. A. Parmin, U. Hashim, Subash C. B. Gopinath, et al.
Microchimica Acta (2019) Vol. 186, Iss. 6
Open Access | Times Cited: 39
Prevalence, incidence, and natural history of HPV infection in adult women ages 24 to 45 participating in a vaccine trial
Daron G. Ferris, Darron R. Brown, Anna R. Giuliano, et al.
Papillomavirus Research (2020) Vol. 10, pp. 100202-100202
Open Access | Times Cited: 39
Efficacy of photodynamic therapy for warts induced by human papilloma virus infection: A systematic review and meta-analysis
Sihao Shen, Jiangfeng Feng, Xiuzu Song, et al.
Photodiagnosis and Photodynamic Therapy (2022) Vol. 39, pp. 102913-102913
Closed Access | Times Cited: 21
The BD Onclarity HPV Assay on Samples Collected in SurePath Medium Meets the International Guidelines for Human Papillomavirus Test Requirements for Cervical Screening
Ditte Møller Ejegod, Fabio Bottari, Helle K. Pedersen, et al.
Journal of Clinical Microbiology (2016) Vol. 54, Iss. 9, pp. 2267-2272
Open Access | Times Cited: 35
Human papillomavirus detection in cervical neoplasia attributed to 12 high-risk human papillomavirus genotypes by region
Xavier Castellsagué, Kevin A. Ault, F. Xavier Bosch, et al.
Papillomavirus Research (2016) Vol. 2, pp. 61-69
Open Access | Times Cited: 34
Antibody persistence and evidence of immune memory at 5 years following administration of the 9-valent HPV vaccine
Ana María Agudelo Guevara, Robinson Cabello, Linn Woelber, et al.
Vaccine (2017) Vol. 35, Iss. 37, pp. 5050-5057
Open Access | Times Cited: 34
Human Papillomavirus Genotypes From Vaginal and Vulvar Intraepithelial Neoplasia in Females 15–26 Years of Age
Suzanne M. Garland, Elmar A. Joura, Kevin A. Ault, et al.
Obstetrics and Gynecology (2018) Vol. 132, Iss. 2, pp. 261-270
Closed Access | Times Cited: 34
A Lab-on-a-Chip Device Integrated DNA Extraction and Solid Phase PCR Array for the Genotyping of High-Risk HPV in Clinical Samples
Cancan Zhu, Anzhong Hu, Junsheng Cui, et al.
Micromachines (2019) Vol. 10, Iss. 8, pp. 537-537
Open Access | Times Cited: 33
Human Papillomaviruses-Related Cancers: An Update on the Presence and Prevention Strategies in the Middle East and North African Regions
Queenie Fernandes, Soumaya Allouch, Ishita Gupta, et al.
Pathogens (2022) Vol. 11, Iss. 11, pp. 1380-1380
Open Access | Times Cited: 18
Impact of high‐risk Human Papillomavirus genotyping in cervical disease in the Northern region of Portugal: Real‐world data from regional cervical cancer screening program
Andreia Rosário, Ana Rita Sousa, Joana Marinho‐Dias, et al.
Journal of Medical Virology (2022) Vol. 95, Iss. 1
Open Access | Times Cited: 17
Human papillomavirus vaccination coverage in Northeast Brazil, 2013-2021: a descriptive study
Mateus de Paula von Glehn, Luciana Maiara Diogo Nascimento, Krishna Mara Rodrigues Freire, et al.
Epidemiologia e Serviços de Saúde (2023) Vol. 32, Iss. 2
Open Access | Times Cited: 10
Impact of HPV Catch-Up Vaccination on High-Grade Cervical Lesions (CIN2+) Among Women Aged 26–30 in Northern Norway
Anne Jørgensen, Gunnar Skov Simonsen, Sveinung Wergeland Sørbye
Vaccines (2025) Vol. 13, Iss. 1, pp. 96-96
Open Access
Human Papillomaviruses
Adriana Cadilla, Linette Sande, Kenneth Alexander
Elsevier eBooks (2025), pp. 1414-1429.e8
Closed Access
Risk‐Based Triage Strategy by Extended HPV Genotyping for Women With LSIL Cytology: A Real‐World Study
Chun Ye, Yi Liu, Hefeng Huang, et al.
Journal of Medical Virology (2025) Vol. 97, Iss. 5
Open Access

Scroll to top